- Market Capitalization, $K 114,288
- Shares Outstanding, K 31,924
- Annual Sales, $ 500 K
- Annual Income, $ -16,850 K
- 60-Month Beta 2.48
- Price/Sales 234.96
- Price/Cash Flow N/A
- Price/Book 6.64
|Period||Period Low||Period High||Performance|
| || |
+0.25 (+7.51%)since 06/10/20
| || |
+2.59 (+260.67%)since 04/09/20
| || |
+1.79 (+100.00%)since 07/10/19
, /PRNewswire/ --Read the full report: As on date of publishing, this report will capture the impact assessment of COVID-19 on this market and the same will be considered in our market forecast model....
Celsion Corporation (NASDAQ: CLSN), an oncology drug-development company, today affirmed that the independent Data Monitoring Committee (iDMC) is scheduled to meet during the first half of July to conduct...
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced the closing of its previously announced public offering of 2,666,667 shares of common stock, resulting in net proceeds...
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced the entry into an underwriting agreement relating to the sale of 2,666,667 shares of its common stock at an offering...
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CLSN, WTER, SALM, OCUL, and DAL.
Investors need to pay close attention to Celsion (CLSN) stock based on the movements in the options market lately.
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for OVID, CLSN, ALRN, CRON, and BAC.
Excellent Surgical Response Noted at the Higher, 100 mg/mDose
Given the improvements in domestic economy, small-cap stocks led the way higher last week.
Phase III OPTIMA Study on Track for Interim Data Analysis in July